Skip to main content
Glama

AlpineDataWorks Intelligence Server

Clinical-Trial Activity

adw.adw_124
Read-only

Returns a 0-100 US clinical-trial pipeline activity score (composite z-score of ClinicalTrials.gov active trial volume, phase distribution, and registration momentum; weekly since 2000) with top_drivers by trial phase (late-stage Phase 3 vs early Phase 1), percentile, and methodology_version. Call when the user asks about clinical trials, drug development pipelines, biotech or pharma R&D activity, or when timing biotech sector-rotation or investment-screening decisions. Updates: weekly.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
daysNoOptional: return a daily HISTORY series of the last N days (up to 5 years of real archived data) instead of the current snapshot. History requires Gold tier; without it, the current snapshot is returned.

TDQS

A4.2/5.0
Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate readOnlyHint=true, so no contradiction. The description adds valuable behavioral context beyond annotations: the score is a composite z-score, weekly since 2000, and includes top_drivers, percentile, and methodology_version. It does not over-explain trivialities, but it could also mention the optional history behavior (Gold tier) which is left to the schema, so a 4 is appropriate.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is well-structured and efficient. The first sentence delivers the core functionality, the second provides usage context, and the third is a brief update frequency note. Every sentence earns its place, with no redundancy or filler, making it easy for an agent to parse quickly.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

The description is complete for a read-only tool with no output schema. It explains the main return components (top_drivers, percentile, methodology_version) and gives clear use cases. The only missing piece is a more explicit description of the default snapshot vs. the optional history series, but the schema covers that. Given the tool's moderate complexity, this is sufficiently complete.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100% for the single 'days' parameter, which already describes its purpose, range, and Gold tier requirement. The tool description does not add any extra meaning about the parameter; it only implies the default snapshot behavior through the primary return description. This meets the baseline of 3 but does not exceed it.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description is highly specific: 'Returns a 0-100 US clinical-trial pipeline activity score' with a detailed definition of the composite z-score and its components (active trial volume, phase distribution, registration momentum). It clearly communicates the tool's unique output, distinguishing it from any sibling tools through its precise resource and metrics.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It provides explicit when-to-use guidance: 'Call when the user asks about clinical trials, drug development pipelines, biotech or pharma R&D activity, or when timing biotech sector-rotation or investment-screening decisions.' However, it does not mention when not to use the tool or name any alternative sibling tools, so it falls short of a 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.3/5.0
Disambiguation1/5

With 318 tools named adw.adw_###, agents cannot tell them apart without reading full descriptions. Multiple tools cover the same domain (e.g., at least three USD strength scores: adw_055, adw_250, adw_580; four supply-chain stress scores: adw_009, adw_019, adw_020, adw_547), making misselection highly likely.

Naming Consistency3/5

The vast majority follow a consistent numeric ID pattern (adw.adw_###), but a small set breaks this with descriptive snake_case names (adw.catalog, adw.sample, adw.county_cancer, etc.). The numeric IDs are predictable but convey no semantic meaning, mixing with the few named tools and creating moderate inconsistency.

Tool Count1/5

318 tools is far beyond any reasonable scope for an intelligence server; even the largest sophisticated APIs rarely exceed 50. This extreme count suggests poor curation and will overwhelm agents with choice, making efficient tool selection impractical.

Completeness3/5

The server covers an extremely broad range of domains (crypto, macro, supply chain, healthcare, climate, county demographics), and includes discovery tools like adw.catalog and adw.sample. However, the surface is redundant and not systematically complete—many overlapping indices exist while other potentially valuable operations (e.g., raw data export, historical trend queries) are missing, leaving moderate gaps.

Resources